In a patient on basal insulin with fasting glucose around 70 mg/dL, should metformin be stopped when starting a GLP‑1 receptor agonist, and how should the metformin dose be adjusted based on renal function?

Do Not Stop Metformin When Starting a GLP-1 Receptor Agonist

Metformin should be continued when initiating a GLP-1 receptor agonist, provided the patient's renal function permits its use (eGFR ≥30 mL/min/1.73 m²). The current treatment paradigm explicitly positions GLP-1 RAs as add-on therapy to metformin, not as replacement therapy.

The Evidence-Based Treatment Algorithm

The KDIGO 2022 guidelines establish a clear hierarchy: first-line treatment for type 2 diabetes with CKD includes both metformin AND an SGLT2 inhibitor, with GLP-1 RAs added as needed for glycemic control 1. This framework explicitly states that GLP-1 RAs are recommended "despite use of metformin and SGLT2i treatment, or who are unable to use those medications" 1. The algorithm never suggests stopping metformin when adding a GLP-1 RA.

The 2025 ADA Standards reinforce this approach, stating that when combination injectable therapy is initiated, "metformin therapy should be continued" 2. The AACE 2023 algorithm similarly positions GLP-1 RAs as additions to ongoing metformin therapy, not replacements 3.

Critical Context: Your Patient on Basal Insulin with Fasting Glucose ~70 mg/dL

This clinical scenario requires immediate attention to hypoglycemia risk, not metformin discontinuation:

• The basal insulin dose needs reduction when adding a GLP-1 RA, not the metformin 1
• Practice Point 4.2.4 from KDIGO explicitly warns: "The risk of hypoglycemia is generally low with GLP-1 RA when used alone, but risk is increased when GLP-1 RA is used concomitantly with other medications such as sulfonylureas or insulin. The doses of sulfonylurea and/or insulin may need to be reduced" 1
• With fasting glucose already at 70 mg/dL, continuing current insulin doses while adding a GLP-1 RA creates significant hypoglycemia risk

Metformin Dosing Based on Renal Function

Adjust metformin based solely on eGFR, not on the addition of other glucose-lowering agents 1, 4:

eGFR-Based Dosing Algorithm:

• eGFR ≥60 mL/min/1.73 m²: Continue current metformin dose
• eGFR 45-59 mL/min/1.73 m²: Consider dose reduction in certain conditions (elderly, heart failure, liver disease)
• eGFR 30-44 mL/min/1.73 m²: Halve the metformin dose
• eGFR <30 mL/min/1.73 m²: Stop metformin; contraindicated 4

Additional Metformin Considerations:

• Do not initiate metformin if eGFR is between 30-45 mL/min/1.73 m² 4
• Monitor eGFR at least annually, or every 3-6 months if eGFR <60 1
• Monitor vitamin B12 levels if on metformin >4 years 1

The Rationale for Continuing Metformin

Metformin and GLP-1 RAs have complementary mechanisms that provide additive benefits:

• Metformin reduces hepatic glucose production and improves insulin sensitivity
• GLP-1 RAs enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety
• Both agents carry low hypoglycemia risk when used without insulin or sulfonylureas
• Both are weight-neutral or promote weight loss 5

Recent real-world data supports this approach: a 2026 study found that continuing metformin when adding imeglimin (another glucose-lowering agent) was associated with significantly greater HbA1c reduction (-0.6% vs -0.2%) compared to reducing metformin dose 6. The absolute metformin dose reduction correlated directly with smaller HbA1c improvements.

Common Pitfalls to Avoid

1. Do not stop metformin reflexively when adding any new glucose-lowering agent unless contraindicated by renal function or intolerance
2. Do not confuse the need to reduce insulin doses with a need to stop metformin when adding GLP-1 RAs
3. Do not use cost or "simplification" as justification to stop metformin in favor of more expensive agents—metformin remains first-line therapy 5
4. Do not forget to temporarily discontinue metformin before iodinated contrast procedures if eGFR 30-60 mL/min/1.73 m² 4

Practical Implementation for Your Patient

For a patient on basal insulin with fasting glucose ~70 mg/dL starting a GLP-1 RA:

1. Continue metformin at current dose (if eGFR ≥30 and no contraindications)
2. Reduce basal insulin by 20% if HbA1c ≤8% to prevent hypoglycemia 7
3. Start GLP-1 RA at lowest dose and titrate slowly to minimize GI side effects 1
4. Monitor fasting glucose closely and adjust insulin further as needed
5. Check eGFR to confirm metformin dosing remains appropriate

The only scenario where metformin should be stopped is if eGFR falls below 30 mL/min/1.73 m² or if the patient develops contraindications (severe hepatic disease, acute illness with risk of lactic acidosis, intolerance) 4.